High trading volume signals potential growth

If investing were easy, everyone would do it and we would all be rich. But is not so. Investing takes time, patience and effort, which is the goal now. Among the investment tools provided by Marketbeat is a screening for unusual volume activity. Unusually high volume is often a precursor to accelerating stock price movement, so it is a valuable tool.

However, investors will find the list of unusual assets chock-full of nonsense, such as SPACS and ETFs with no deals, and hopes other than those inspired by increased volumes. An increase in volume is one thing, but a 1000% increase doesn’t mean much if only a few people buy. However, by applying a little due diligence you will be able to obtain numerous opportunities of true value; all it takes is a little effort. Here’s a look at three recently featured stocks with triple-digit volume spikes or better.

Candel Therapeutics has four-digit peak volume

Candle therapy NASDAQ:CADL develops immunotherapies for cancer patients and is advancing its technology. This biopharmaceutical company recently reported a four-digit increase in its trading volume, a 2500% increase from 140,000 to over 3.75 million, thanks to positive results from a clinical trial.

An interim test of its lead candidate showed a significant increase in survival rates at the critical limits of 24 and 28 months for non-metastatic pancreatic cancer. Survival at 24 months exceeded 70% compared to only 17% in the control group. Furthermore, no new safety concerns were raised, suggesting that the drug can be used in multiple doses without toxicity.

This is the third increase in price and volume for this stock since the fourth quarter of 2023 and the cumulative result is a bottom and market reversal. The latest surge is on track to push volume to a record level and push the price action up nearly 35%. Since the volume is so strong and the technical signals solid, the stock price will likely rise to $3 and perhaps move above it. Technical indications include the bullish Stochastic and MACD, both still low in their respective ranges, and support at the convergence of the 30-day and 150-day EMAs.

Marketbeat only tracks one analyst with a rating on Candel, but sentiment is bullish and price action is in line with forecasts. HC Wainwright has the stock pegged at Buy with a price target of $11 or nearly 400% upside.

MSP recovery has a recovery in progress

MSP recovery NASDAQ: LIFW is a health-focused data solutions platform whose volume recently increased by more than 500%. The cause is revelation Palantir NYSE:PLTR had taken a 6.5% stake in the company. There’s no word on Palantir’s intentions, but the message is clear: The market-leading AI-driven data analytics company believes this stock is a good buy.

MSP Recovery is generating revenue but has not yet turned a profit. The outlook for 2024 and 2025 is for growth to accelerate at a breakneck pace and for profits to soon follow. Opportunities for investors include the acquisition of MSP Recovery by Palantir or another AI data processor. Palantir is an obvious choice because it is geared toward private sector operations that include healthcare.

Perma-Fix Environmental Solutions Volume Peaks of 400%

Perma-Fix environmental solutions NASDAQ: PESI volume has soared since the beginning of the year and recently increased by 400%. The lawsuit is a pivot to profits that precedes what the company’s CEO has described as a transformational year. Recent news includes the successful testing of a pilot plant to destroy “chemicals forever”, a potentially billion-dollar business. No analysts rate this stock, but the institutional side is taking an interest. Institutional inflows have outpaced outflows for more than two years, and activity has increased over the past three quarters. Institutions own about 25% of shares; the property is large and growing.

Before you consider Candel Therapeutics, you’ll want to hear this.

MarketBeat tracks daily Wall Street’s highest-rated and best-performing research analysts and the stocks they recommend to their clients. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market takes hold… and Candel Therapeutics wasn’t on the list.

While Candel Therapeutics currently has a “buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View the five stocks here